Guggenheim Reiterates Buy on Immunovant, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja has reiterated a 'Buy' rating on Immunovant (NASDAQ:IMVT) and maintained a price target of $32.
September 22, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst has reiterated a 'Buy' rating on Immunovant and maintained a price target of $32.
The reiteration of a 'Buy' rating by a Guggenheim analyst and the maintenance of a $32 price target indicates a positive outlook for Immunovant. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100